A study has found that patients using GLP-1 receptor agonists (GLP-1 RAs) like Wegovy and Mounjaro lose significantly fewer pounds compared to clinical trials. Analyzing over 51,000 patients eligible for both weight loss surgery and jabs, researchers revealed that those who underwent bariatric surgery experienced a 26.5% average body weight reduction after two years, while GLP-1 RA users saw only 5.7%. The findings have not been peer-reviewed yet and highlight a potential gap between clinical effectiveness and real-world outcomes, as emphasized by study author Dr. Karan Chhabra.
The most reliable way to lose 20% to 30% of your weight is to get a bariatric operation.
In the real world, patients on GLP-1 RAs are not achieving the weight loss seen in clinical trials.
Collection
[
|
...
]